Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Author Verified
ACE Report #6146
Ace Report Cover General Orthopaedics

Teriparatide increases hip & spine BMD, particularly in type I osteogenesis imperfecta

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Evaluation of teriparatide treatment in adults with osteogenesis imperfecta

J Clin Invest. 2014 Feb 3;124(2):491-8. doi: 10.1172/JCI71101.

Contributing Authors: ES Orwoll J Shapiro S Veith Y Wang J Lapidus C Vanek JL Reeder TM Keaveny DC Lee MA Mullins SC Nagamani B Lee

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


79 patients with osteogenesis imperfecta (OI) were randomized to receive either teriparatide (recombinant human parathyroid hormone) or a placebo administered subcutaneously daily for 18 months. The purpose of this proof-of-concept study was to determine whether teriparatide increased bone formation and positively affected skeletal mass and strength versus a placebo. The results at 18 months indic...

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.